OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy
Laura Gianolio, Katherine Armstrong, Ewan Swann, et al.
Journal of Pediatric Gastroenterology and Nutrition (2023) Vol. 77, Iss. 2, pp. 235-239
Closed Access | Times Cited: 9
Laura Gianolio, Katherine Armstrong, Ewan Swann, et al.
Journal of Pediatric Gastroenterology and Nutrition (2023) Vol. 77, Iss. 2, pp. 235-239
Closed Access | Times Cited: 9
Showing 9 citing articles:
Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System
H. Jourdain, Léa Hoisnard, É. Sbidian, et al.
World Journal of Pediatrics (2025)
Closed Access
H. Jourdain, Léa Hoisnard, É. Sbidian, et al.
World Journal of Pediatrics (2025)
Closed Access
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease
S Vuijk, M Jongsma, Britt M. Hoeven, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 12, pp. 1510-1520
Closed Access | Times Cited: 3
S Vuijk, M Jongsma, Britt M. Hoeven, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 12, pp. 1510-1520
Closed Access | Times Cited: 3
How can we improve the carbon footprint of IBD clinical care?
Isabel Carbery, Gauraang Bhatnagar, Rachel Cooney, et al.
Frontline Gastroenterology (2024) Vol. 15, Iss. e1, pp. e55-e61
Closed Access | Times Cited: 2
Isabel Carbery, Gauraang Bhatnagar, Rachel Cooney, et al.
Frontline Gastroenterology (2024) Vol. 15, Iss. e1, pp. e55-e61
Closed Access | Times Cited: 2
Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context
Zvonimir Petrić, João Gonçalves, Paulo Paixão
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1974-1974
Open Access | Times Cited: 1
Zvonimir Petrić, João Gonçalves, Paulo Paixão
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1974-1974
Open Access | Times Cited: 1
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress
Debora Curci, Marianna Lucafò, Giuliana Decorti, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Debora Curci, Marianna Lucafò, Giuliana Decorti, et al.
Expert Opinion on Biological Therapy (2024)
Closed Access | Times Cited: 1
Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost‐effective strategy? Authors' reply
S Vuijk, Lissy de Ridder
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 95-96
Closed Access
S Vuijk, Lissy de Ridder
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 1, pp. 95-96
Closed Access
Considerations in Paediatric and Adolescent Inflammatory Bowel Disease
S Vuijk, A Camman, Lissy de Ridder
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. Supplement_2, pp. ii31-ii45
Open Access
S Vuijk, A Camman, Lissy de Ridder
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. Supplement_2, pp. ii31-ii45
Open Access
Biologics in the management of pediatric inflammatory bowel disease: When and what to choose
Arghya Samanta, Anshu Srivastava
World Journal of Clinical Pediatrics (2024) Vol. 14, Iss. 1
Closed Access
Arghya Samanta, Anshu Srivastava
World Journal of Clinical Pediatrics (2024) Vol. 14, Iss. 1
Closed Access
How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?
Ivan Foeldvari, Harry Petrushkin
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 267-276
Closed Access | Times Cited: 1
Ivan Foeldvari, Harry Petrushkin
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 267-276
Closed Access | Times Cited: 1
